Drug Discovery

Vor Biopharma closes $110m Series B financing

Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, announced it has raised $110 million in a Series B financing.

Goldfinch Bio raises $100m to develop therapies for kidney diseases

Goldfinch Bio has raised $100m in a Series B funding round for the discovery and development of precision drugs for the treatment of kidney diseases.

Low Maintenance pH Electrodes and Systems

METTLER TOLEDO follows in the tradition of INGOLD by continuing to provide innovative new products and systems based on decades of accumulated knowledge and experience in industrial measurement technology.

Symbiosis and AstraZeneca sign supply agreement for sterile manufacture of Covid-19 vaccine for clinical trials

Symbiosis Pharmaceutical Services, a specialist provider of pharmaceutical and vaccine development services, has announced it has signed a supply agreement with AstraZeneca for sterile manufacture of the Covid-19 recombinant adenovirus vaccine known as AZD1222 for AstraZeneca sponsored clinical trials.

Sanofi, Translate Bio expand mRNA vaccine partnership in $2.3bn worth deal

Sanofi Pasteur has signed a fresh deal potentially worth up to $2.32bn with US-based Translate Bio to expand an existing partnership of developing vaccines for infectious diseases by using the latter's messenger RNA technology (mRNA technology).

Frontier Scientific, Renibus Therapuetics to develop Covid-19 therapeutic

Frontier Scientific, a world leader in porphyrin chemistry and chemical building blocks for drug discovery and material science research, announced their collaboration with Renibus Therapuetics to develop a therapeutic for Covid-19.

Gilead Sciences to buy 49.9% stake in Pionyr Immunotherapeutics for $275m

US-based biopharmaceutical company Gilead Sciences has agreed to acquire 49.9% equity stake in Pionyr Immunotherapeutics for $275m.

Elemental Packaging

After transferring the media slurry into the open column, the piston is quickly mounted in a way that avoids air entry, and the column is sealed.

Interdisciplinary consortium receives grant to develop next-generation cell-based cancer vaccines

Cell-based cancer vaccines are revolutionizing the treatment of previously incurable cancers. Access to these promising therapies is limited by the high costs of manufacturing at centralized locations. Saint-Gobain Life Sciences, Kanyr Pharma Inc., the RI-MUHC and McGill University have formed a new interdisciplinary consortium to make this technology more accessible. In this project, dendritic cell cancer vaccines will be generated in Saint-Gobain’s VueLife® “C” Series FEP bags.